Table 2.
Predictive factors for LDA achievement at 52 weeks.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| OR | p value | Adjusted OR | p value | |
| Age | 0.99 (0.98–1.01) | 0.439 | 1.00 (0.97–1.02) | 0.749 |
| Male (vs. female) | 1.12 (0.70–1.80) | 0.634 | 0.79 (0.40–1.58) | 0.511 |
| Disease duration | 0.99 (0.97–1.00) | 0.053 | 0.99 (0.97–1.01) | 0.468 |
| Bio-naïve | 1.23 (0.81–1.85) | 0.335 | 1.18 (0.67–2.08) | 0.575 |
| MTX use | 1.12 (0.75–1.69) | 0.585 | 1.14 (0.66–1.95) | 0.649 |
| PSL use | 0.82 (0.55–1.23) | 0.329 | 0.97 (0.58–1.64) | 0.923 |
| SDAI at baseline | 0.96 (0.94–0.97) | < 0.001 | 0.96 (0.94–0.98) | < 0.001 |
| mHAQ | 0.50 (0.36–0.69) | < 0.001 | 0.57 (0.38–0.86) | 0.008 |
| ACPA-positive | 2.03 (1.29–3.17) | 0.002 | 2.61 (1.36–5.00) | 0.004 |
LDA low disease activity, OR odds ratio, MTX methotrexate, PSL prednisolone, SDAI simplified disease activity index, mHAQ modified health assessment questionnaire, ACPA anti-citrullinated protein/peptide antibody.